+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are collecting safety and performance data on the PRESERFLO MicroShunt XI device in patients with primary open angle glaucoma whose intraocular pressure IOP is not adequately controlled despite maximum tolerated medical therapy. This study focuses on patients with IOP between 18 and 35 mmHg or those whose glaucoma progression requires surgery. The study is a prospective, multicenter, single-arm post-market follow-up to evaluate this CE-marked device designed for glaucoma treatment. The PRESERFLO MicroShunt XI is a small implantable device that creates a passageway to drain aqueous humor from the eyes anterior chamber to a bleb beneath the conjunctiva, helping to reduce eye pressure. The device is surgically implanted by trained ophthalmologists or surgeons specializing in glaucoma or anterior segment surgery. There is no control group, and no biospecimens are collected as part of this study. Participants will undergo surgical implantation of the MicroShunt XI and be followed over time to monitor safety and performance. Researchers will assess changes in intraocular pressure up to 12 months after surgery. No additional ocular surgeries are planned during the study period. The study includes regular visits to evaluate eye health, monitor adverse events, and collect performance data, with participant involvement lasting up to 12 months.

Age: 18Years - 85YearsAll Genders
12 locations
E

Actively Recruiting

Researchers are evaluating the safety and performance of the WhiteSwell eLym System for treating fluid overload or congestion in adults hospitalized with Acute Decompensated Heart Failure ADHF. This feasibility study focuses on assessing both acute and chronic device safety, as well as the technical success and patient treatment outcomes related to this device. The WhiteSwell eLym System is a device designed to reduce congestion by creating a low-pressure zone at the thoracic duct outflow, which helps move fluid from the lymphatic system back into the bloodstream. The device consists of a catheter and sheath used with a console and is temporarily placed for up to 60 hours via the left internal jugular vein while patients continue receiving intravenous diuretics. This treatment occurs during hospitalization, with the device placed in a heart catheterization laboratory. Participants will be monitored during their hospital stay and followed up at 30, 60, 90, and 180 days after discharge. Researchers will assess safety by tracking serious adverse events related to the device and treatment, technical success of device placement and removal, as well as changes in body weight, fluid levels, kidney function, lung water, and heart failure therapy needs. Additionally, quality of life and biomarker levels will be evaluated to understand long-term outcomes, including the time to rehospitalization for heart failure.

Age: 18Years +All GendersPhase Not Applicable
11 locations